Literature DB >> 1651286

Monoclonal antibodies to Kunjin and Kokobera viruses.

R A Hall1, G W Burgess, B H Kay, P Clancy.   

Abstract

Five monoclonal antibodies (MoAb) were produced to the envelope (E) protein of Kunjin (KUN) virus. Three of these were specific for the KUN/West Nile complex, and two reacted with epitopes that were common to the flavivirus family. These MoAb defined at least four distinct epitopes on the E protein of KUN virus. Eight MoAb were also produced to unidentified proteins of Kokobera (KOK) virus. Seven were specific for KOK, while the remaining antibody cross-reacted with Stratford virus and an unregistered flavivirus CS946. The application of these MoAb to arboviral surveillance is discussed.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1651286     DOI： 10.1038/icb.1991.7

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN： 0818-9641            Impact factor:   5.126


  16 in total

1.  Detection of West Nile virus antigen in mosquitoes and avian tissues by a monoclonal antibody-based capture enzyme immunoassay.

Authors:  Ann R Hunt; Roy A Hall; Amy J Kerst; Roger S Nasci; Harry M Savage; Nicholas A Panella; Kristy L Gottfried; Kristen L Burkhalter; John T Roehrig
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus.

Authors:  Roy A Hall; Debra J Nisbet; Kim B Pham; Alyssa T Pyke; Greg A Smith; Alexander A Khromykh
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-13       Impact factor: 11.205

Review 3.  Molecular epidemiology and evolution of mosquito-borne flaviviruses and alphaviruses enzootic in Australia.

Authors:  J S Mackenzie; M Poidinger; M D Lindsay; R A Hall; L M Sammels
Journal:  Virus Genes       Date:  1995       Impact factor: 2.332

4.  A novel bacterium-free method for generation of flavivirus infectious DNA by circular polymerase extension reaction allows accurate recapitulation of viral heterogeneity.

Authors:  Judith Edmonds; Erinke van Grinsven; Natalie Prow; Angela Bosco-Lauth; Aaron C Brault; Richard A Bowen; Roy A Hall; Alexander A Khromykh
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

5.  Noncoding Subgenomic Flavivirus RNA Is Processed by the Mosquito RNA Interference Machinery and Determines West Nile Virus Transmission by Culex pipiens Mosquitoes.

Authors:  G P Göertz; J J Fros; P Miesen; C B F Vogels; M L van der Bent; C Geertsema; C J M Koenraadt; R P van Rij; M M van Oers; G P Pijlman
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

6.  Epitope-blocking enzyme-linked immunosorbent assays for the detection of serum antibodies to west nile virus in multiple avian species.

Authors:  Bradley J Blitvich; Nicole L Marlenee; Roy A Hall; Charles H Calisher; Richard A Bowen; John T Roehrig; Nicholas Komar; Stanley A Langevin; Barry J Beaty
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

7.  NS1 protein secretion during the acute phase of West Nile virus infection.

Authors:  Joanne Macdonald; Jessica Tonry; Roy A Hall; Brent Williams; Gustavo Palacios; Mundrigi S Ashok; Omar Jabado; David Clark; Robert B Tesh; Thomas Briese; W Ian Lipkin
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

8.  Development of monoclonal antibodies to West Nile virus and their application in immunohistochemistry.

Authors:  Jiro Hirota; Shinya Shimizu; Tomoyuki Shibahara; Takashi Isobe; Manabu Yamada; Nobuhiko Tanimura
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

9.  The relationships between West Nile and Kunjin viruses.

Authors:  J H Scherret; M Poidinger; J S Mackenzie; A K Broom; V Deubel; W I Lipkin; T Briese; E A Gould; R A Hall
Journal:  Emerg Infect Dis       Date:  2001 Jul-Aug       Impact factor: 6.883

10.  CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis.

Authors:  Yang Wang; Mario Lobigs; Eva Lee; Arno Müllbacher
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.